PAD Forum: Debates and Controversies

Panelist(s)

• 

  Daniella Kadian-Dodov, MD

  Associate Professor of Medicine
  Icahn School of Medicine at Mount Sinai, New York, United States
• RL

  Rebecca LeLeiko, MD, MS

  Assistant Professor
  Emory University School of Medicine, Georgia, United States
• 

  Christopher Regan, MD

  Associate Professor
  Yale University, Connecticut, United States

Speaker(s)

• 

  Herbert Aronow, MD, MPH

  Medical Director, Heart & Vascular Services
  Heart & Vascular Service Line
  Henry Ford Health, Michigan, United States
• JB

  Jocelyn Beach, MD
• NB

  Nelson Bernado
• 

  Marc Bonaca, MD, MPH

  Professor of Medicine
  University of Colorado School of Medicine, Colorado, United States
• 

  Katharine McGinigle, MD, MPH

  Associate Professor
  UNC, North Carolina, United States

Presentations:

• 1:10 PM – 1:22 PM EDT

  Similar or Different: US Versus European Guidelines for the Management of PAD
  

  Speaker: Herbert Aronow, MD, MPH – Henry Ford Health
• 1:22 PM – 1:24 PM EDT

  Audience Poll
• 1:24 PM – 1:29 PM EDT

  Intervention for Symptomatic Common Femoral Artery Stenosis: Endovascular Approach Should Be Firstline Intervention
  

  Speaker: Nelson L. Bernado
• 1:29 PM – 1:34 PM EDT

  Intervention for Symptomatic Common Femoral Artery Stenosis: Surgical Approach Should Be Firstline Intervention
  

  Speaker: Katharine L. McGinigle, MD, MPH – UNC
• 1:34 PM – 1:36 PM EDT

  Intervention for Symptomatic Common Femoral Artery Stenosis Rebuttal
  

  Speaker: Nelson L. Bernado
• 1:36 PM – 1:38 PM EDT

  Intervention for Symptomatic Common Femoral Artery Stenosis Rebuttal
  

  Speaker: Katharine L. McGinigle, MD, MPH – UNC
• 1:38 PM – 1:40 PM EDT

  Audience Poll
• 1:40 PM – 1:42 PM EDT

  Audience Poll
• 1:42 PM – 1:47 PM EDT

  Dual Pathway Inhibition Post Revascularization: DPI Should Be Prescribed Routinely Post Lower Extremity Revascularization
  

  Speaker: Jocelyn M. Beach, MD
• 1:47 PM – 1:52 PM EDT

  Dual Pathway Inhibition Post Revascularization: DPI Should Not Be Prescribed Routinely Post Lower Extremity Revascularization
  

  Speaker: Marc Bonaca, MD, MPH – University of Colorado School of Medicine
• 1:52 PM – 1:54 PM EDT

  Dual Pathway Inhibition Post Revascularization Rebuttal
  

  Speaker: Jocelyn M. Beach, MD
• 1:54 PM – 1:56 PM EDT

  Dual Pathway Inhibition Post Revascularization Rebuttal
  

  Speaker: Marc Bonaca, MD, MPH – University of Colorado School of Medicine
• 1:56 PM – 1:58 PM EDT

  Audience Poll
• 1:58 PM – 2:04 PM EDT

  Rapid Fire Questions: Initial Test for CLI: ABI, US, CTA, MRA, or Angiogram
  

  Panelist: Daniella Kadian-Dodov, MD – Icahn School of Medicine at Mount Sinai

  Panelist: Rebecca LeLeiko, MD, MS – Emory University School of Medicine

  Panelist: Christopher Regan, MD – Yale University
• 2:04 PM – 2:10 PM EDT

  Rapid Fire Questions: Below the Knee Disease Always Endovascular First; YES or NO
  

  Panelist: Daniella Kadian-Dodov, MD – Icahn School of Medicine at Mount Sinai

  Panelist: Rebecca LeLeiko, MD, MS – Emory University School of Medicine

  Panelist: Christopher Regan, MD – Yale University